Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of MenACWY-TT booster versus Hib-MenCY-TT booster in toddlers primed with Hib-MenCY-TT, with later Infanrix co-administration assessment
2012-002401-22Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine in meningococcal disease and Haemophilus influenzae type b disease (Hib) (4 arms), sponsored by GSK. Primary endpoint: hSBA seroprotection/response for meningococcal serogroups.
02
Drugs
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine
03
Conditions
meningococcal diseaseHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2012-002401-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002401-22.